TAP gene transporter polymorphism in inflammatory bowel diseases

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 10, 1997, Pages 1022-1027

  Heresbach, D ^a   Alizadeh, M ^b   Bretagne, J F ^b   Dabadie, A ^b   Colombel, J F ^b   Pagenault, M ^b   Heresbach Le Berre, N ^b   Genetet, B ^b   Gosselin, M ^b   Semana, G ^b  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

Inflammatory bowel disease; TAP genes

Indexed keywords

ADULT; ALLELE; ALLELISM; ARTICLE; CHROMOSOME 6; CONTROLLED STUDY; ENTERITIS; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TRANSPORT; STEROID THERAPY;

EID: 15644370484     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709011219     Document Type: Article

References (45)

1. Toyoda H, Wang SJ, Yang H, Redford A, Malagong D, Tyan D, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;29:990-6.
2. Yang H, Rotter JI. The genetics of inflammatory bowel disease. In: Targan SR, Shanahan F, editors. Inflammatory bowel disease: from bench to-bedside. Baltimore: Williams and Wilkins; 1994. p. 32-64.
3. Duerr RH, Neigut DA. Molecular defined HLA-DR2 alleles in ulcerative colitis and an anti-neutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 1995;108:423-7.
4. Farrant JM, Bunce M, Arlett C, Landers C, Welsh KI, Toyoda H, et al. HLA DR2 is a susceptibility marker for UC in British patients irrespective of ANCA positivity. Gastroenterology 1994;106:A679.
5. Danze PM, Colombel JF, Jacquot S, Loste MN, Heresbach D, Ategbo S, et al. Distinct HLA-DR genes are associated with susceptibility and resistance to Crohn's disease. Gut 1996;39:69-75.
6. Heresbach D, Alizadeh M, Bretagne JF, Gautier A, Quillivic F, Lemarchand B, et al. Investigation of the association of major histocompatibility complex gene, including HLA class I and class II with clinical forms of Crohn's disease. Eur J Immunogenet 1996;23:141-51.
7. Reinshagen M, Loeliger C, Kuehnl P, Weiss U, Manfras BJ, Adler G, et al. HLA class II gene frequencies in Crohn's disease: a population based analysis in Germany. Gut 1996;38:538-42.
8. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-I receptor antagonist. Gastroenterology 1994;106:637-45.
9. Spies T, Bresnaham M, Bahram S, Arnold D, Blanck G, Mellins E, et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990;348:744-7.
10. Trowsdale J, Hanson I, Mockridge I, Beck S, Towsend A, Kelly A. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature 1990;348:741-4.
11. Bahram S, Arnold D, Bresnahan M, Strominger JL, Spies T. Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region. Proc Natl Acad Sci USA 1991;88:10094-8.
12. Spies T, De Mars R. Restored expression of major histocompatibility class molecules by gene transfer of putative peptide transporter. Nature 1991;351:323-4.
13. Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci USA 1992;89:3932-6.
14. Powis SH, Deverson EV, Coadwell WJ, Ciruela A, Huskisson NS, Smith H, et al. Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature 1992;357:211-5.
15. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 1992;71:1205-14.
16. Powis SJ, Townsend A, Deverson EV, Bastin J, Butcher GW, Howard JC. Restoration of antigen presentation to the mutant cell line RMAS-S by an MHC-linked transporter. Nature 1991;354:528-31.
17. Malnati MS, Marti M, Lavante T, Jaraquemada D, Biddison W, De Mars R, et al. Processing pathway for presentation of cytosolic antigen to MHC class II restricted cells. Nature 1992;357:702-4.
18. Powis SH, Mockridge I, Kelly A, Kerr LA, Glynne R, Gileadi V, et al. Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatibility complex. Proc Natl Sci USA 1992;89:1463-7.
19. Carrington M, Spies T, Stephens JC, Mann DL. Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics 1993;37:266-73.
20. Carrington M, Stephens JC, Klitz W, Begovitch AB, Erlich HA, Mann D. Major histocompatibility complex class II haplotypes and linkage disequilibrium values observed in the CEPH families. Hum Immunol 1994;41:234-40.
21. Ronningen KS, Undlien DE, Ploski R, Maouni N, Konrad RJ, Jensen E, et al. Linkage disequilibrium between TAP2 variants and HLA class II alleles; no primary association between TAP2 variants and insulin-dependent diabetes melitus. Eur J Imunol 1993;23:1050-6.
22. Djilali-Saiah I, Benini V, Daniel S, Assan R, Bach JF, Caillat-Zucman S. Linkage disequilibrium between HLA class II (DR,DQ,DP) and antigen processing (LMP,TAP,DM) genes of the major histocompatibility complex. Tissue Antigens 1996;48:87-92.
23. Caillat-Zucman S, Daniel S, Djilali-Saiah I, Timsit J, Garchon HJ, Boitard C, et al. Family study of linkage disequilibrium between TAP2 transporter and HLA class II genes. Hum Immunol 1995;44:80-7.
24. Modigliani R. Etat actuel du traitement medicamenteux des maladies inflammatoires de l'intestin. In: Modigliani R, editor. Maladies inflammatoires de l'intestin. Paris: Doin; 1988. p. 125-32.
25. Truelove SC, Willoughby CP, Lee EG, Kettlewell MAGW. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1087-8.
26. Modigliani R, Mary JY, Simon JF, Cortot A, Saule JC, Gendre JP, et al. Clinical, biological and endoscopic picture of attacks of Crohn's evolution on prednisolone. Gastroenterology 1990;98:811-8.
27. Munkholm P, Langholz E, Davidson M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
28. Blakemore AIF, Cox A, Gonzalez AM, Maskill JK, Huhes ME, Wilson RM, et al. Interleukin-1 receptor antagonist allele (ILIRN*2) associated with nephropathy in diabetes mellitus. Hum Gen 1996;97:369-74.
29. Moins-Teisserene H, Semana G, Alizadeh M, Loiseau P, Bobrinina V, Edan G, et al. TAP2 gene polymorphism contributes to the genetic susceptibility to multiple sclerosis. Hum Immunol 1995;42:195-202.
30. Kellar-Wood HF, Powis SH, Gray J, Compston DAS. MHC-encoded TAP1 and TAP2 dimorphism in multiple sclerosis. Tissue Antigens 1994;43:129-32.
31. Liblau R, Van Endert PM, Sandberg-Wilheim M. Antigen processing gene polymorphisms in HLA-DR2 multiple sclerosis. Neurology 1993;43:1192-6.
32. Powis SH, Rosenberg WMC, Hall M, Mockridge I, Tonks S, Ivinson A, et al. TAP1 and TAP2 polymorphism in coeliac disease. Immunogenetics 1993;38:345-50.
33. Jackson DG, Capra JD. TAP1 alleles in insulin-dependent diabetes mellitus: a newly defined centromeric boundary of disease susceptibility. Proc Natl Acad Sci USA 1993;90:11079-83.
34. Caillat-Zuckman S, Bertin E, Timsit J, Boitard C, Assan R, Bach JF. Protection from insulin dependent diabetes mellitus is linked to a peptide transporter gene. Eur J Immunol 1993;23:1784-8.
35. Heresbach D, Alizadeh M, Dabadie A, Le Berre N, Colombel JF, Yaouanq J, et al. Significance of interleukin-1β and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 1997;92:1-6.
36. Masuda E, Nakamura Y, Tanaka T, Hayakawa S. Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol 1994;89:1957-62.
37. Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JI, et al. contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-7.
38. Beaugerie L, Lequintrec Y, Paris JC, Godchaux JM, Saint-Raymond A, Schmitz J, et al. Testing for course patterns in Crohn's disease using clustering analysis. Gastroenterol Clin Biol 1989;13:1036-41.
39. Lochs H, Wyatt J, Reinisch W, Gashé Ch, Maier Th, Moser G, et al. Clinical relevance of intestinal permeability in active Crohn's disease. Gastroenterology 1994;106:A508.
40. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-9.
41. Momburg F, Neefjes JJ, Hammerling GJ. Peptide selection by MHC-encoded TAP transporters. Curr Opin Immunol 1994;6:32-7.
42. Androlewicz MJ, Cresswell P. Human transporter associated with antigen processing possess a promiscuous peptide-binding site. Immunity 1994;1:7-14.
43. Momburg F, Roelse J, Howard JC, Butcher GW. Hammerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1994;367:648-51.
44. Momburg F, Roelse J, Hammerling GJ, Neefjes JJ. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J Exp Med 1994;179:1613-23.
45. Wick MJ, Pfeifer JD. Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Eur J Immunol 1996;26:2790-9.